Emergent BioSolutions

Singapore Health Sciences Authority Approves Emergent BioSolutions Anthrax Vaccine, BioThrax

 

Submitted by admin on Thu, 07/07/2011 - 14:59. categories [ ]

Emergent BioSolutions Reports Financial Results for Full Year 2010

  • 2010 revenues of $286.2 million
  • 2010 net income of $51.7 million, or $1.63 per share, representing ninth consecutive year of profitability
  • 2010 cash, investments and accounts receivable balance of $210.4 million
  • 2011 forecast reaffirmed: total revenues of $320 to $340 million and net income of $35 to $45 million

Emergent BioSolutions Inc. (NYSE: EBS) announced on 10 March its financial results for the full year ending December 31, 2010.

Submitted by admin on Wed, 06/22/2011 - 12:51. categories [ ]

Emergent BioSolutions Chairman and CEO Fuad El-Hibri Appointed to U.S. Chamber of Commerce Board of Directors

ROCKVILLE, Md., Jun 13, 2011 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that its Chairman and Chief Executive Officer, Fuad El-Hibri, has been appointed to serve on the Board of Directors of the U.S. Chamber of Commerce. The U.S.
Submitted by admin on Mon, 06/20/2011 - 13:28. categories [ ]

Emergent BioSolutions' Investigational Anthrax Vaccine, NuThrax, Granted Fast Track Designation

 

Submitted by admin on Fri, 06/10/2011 - 13:57. categories [ ]

Emergent BioSolutions on Track to Complete Delivery of 14.5M Doses of BioThrax to the US Government Ahead of Schedule

ROCKVILLE, Md., May 31, 2011 (BUSINESS WIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that eight lots of BioThrax(R) (Anthrax Vaccine Adsorbed) have received regulatory release for delivery to the U.S.
Submitted by admin on Tue, 06/07/2011 - 15:20. categories [ ]

Emergent BioSolutions to Present at Jefferies 2011 Global Healthcare Conference

ROCKVILLE, Md., May 25, 2011 -- Emergent BioSolutions Inc.
Submitted by admin on Wed, 06/01/2011 - 13:45. categories [ ]

Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant in Phase IIb Clinical Trial

  • Total of 2,784 infants vaccinated in TB efficacy trial evaluating MVA85A
  • Study results expected to be available as early as mid-2012

ROCKVILLE, Md., Apr 28, 2011

Submitted by admin on Mon, 05/02/2011 - 15:44. categories [ ]

Emergent BioSolutions to Present Today at Needham & Company Healthcare Conference

Emergent BioSolutions Inc. (NYSE: EBS) will be webcasting its presentation at the 10th Annual Needham & Company Healthcare Conference in New York on Tuesday, April 5, 2011 at 8:00 AM Eastern. During the presentation, a member of the company’s senior management team will provide a corporate overview, which may include a discussion of recent business developments, 2010 financial results and financial guidance for 2011.

Submitted by admin on Tue, 04/05/2011 - 11:27. categories [ ]

Emergent BioSolutions to Release Fourth Quarter and Full Year 2010 Financial Results and Conduct a Conference Call on March 10

ROCKVILLE, Md., Feb 24, 2011 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) announced today it will report financial results for the fourth quarter and full year 2010 on Thursday, March 10, 2011, after market close.

Submitted by admin on Fri, 02/25/2011 - 12:14. categories [ ]

Emergent BioSolutions Starts Phase I Clinical Trial for Third Generation Anthrax Vaccine

ROCKVILLE, Md., Dec 27, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase I clinical trial for NuThraxTM (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject. The product candidate, a third generation vaccine being developed as part of Emergent’s anthrax franchise, consists of BioThrax(R) (Anthrax Vaccine Adsorbed) in combination with a novel immunostimulatory compound, CPG 7909.

Submitted by admin on Wed, 01/05/2011 - 05:30. categories [ ]
1234next ›last »